Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for abdominal-based autologous breast reconstruction (DIEP, MS-TRAM, or TRAM).~* At least 18 years of age.~* Female.~* Able to understand and willing to sign a written informed consent document.~Exclusion Criteria:~* Cognitive impairment.~* History of abdominal surgery precluding free flap donor site.~* Allergy or intolerance to bupivacaine or amide anesthetics.~* Significant preoperative chronic pain (requiring daily narcotics) or neuropathic pain (requiring daily use of pregabalin or gabapentin) within the previous 3 months.~* Pregnant or breastfeeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Bupivicaine (Type: ACTIVE_COMPARATOR): -TAP block of 30 cc of 0.25% bupivicaine
- Group 2: Liposomal bupivacaine (Type: EXPERIMENTAL): -TAP block of 266 mg/30 cc liposomal bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).